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Bone disease in long-term adult kidney transplant patients with Secondary hyperparathyroidism and calcitriol defi-
normal renal function. ciency are the main factors involved in the pathogenesis
Background. In successful renal transplantation, the degree of renal osteodystrophy [1]. Successful renal transplanta-of renal function recovery is usually incomplete and informa-
tion (RT) corrects many of these anomalies, but disor-tion is scarce about the abnormalities of mineral metabolism
ders of bone and mineral metabolism remain a problemin long-term adult renal recipients with normal renal function.
This study was designed to investigate bone mineral metabo- in such patients. Mild persistent hyperparathyroidism is
lism in patients with a long-term normal functioning kidney. common [2] and bone is exposed to new injurious factors,
Methods. Twenty-nine adult asymptomatic renal transplant such as the use of immunosuppresive drugs. Steroid-(RT) recipients with stable graft function for more than 10
induced osteoporosis is multifactorial and has been ex-years and serum creatinine2 mg/dL were studied. They were
tensively described [3]. Moreover, the effects of CsAclassified into two groups according to glomerular filtration
rate: Group A (N  12; nine men, three women) 70 mL/min on bone and mineral metabolism are controversial both
(x: 126  55 mL/min) and Group B (N  17; nine men, eight experimentally and in clinical settings [4–6].
women) 70 mL/min (x: 56  11 mL/min). Circulating bio- This study was designed to investigate bone mineralchemical markers of bone remodelling, bone histomorphome-
metabolism in patients with a long-term normal function-try, and densitometry (lumbar spine and hip) were obtained
ing kidney. In order to minimize the effects of ongoingto investigate bone disease in these patients.
Results. Serum PTH was slightly elevated in 10 patients renal impairment on bone metabolism, we selected pa-
(83%) in group A. Serum PTH levels were positively related tients with creatinine clearance 70 mL/min for further
to serum calcium, osteocalcin, BAP, telopeptide, OH-proline, studies.and creatinine. There was no histologic data to support over-
activity on bone in this group of patients, with only one showing
high bone turnover. Mineralization was prolonged in 34% of
METHODSpatients. Twenty-two patients (75%) exhibited normal bone
turnover. In the group with GFR 70 mL/min the prevalence Subjects
of mineralization defect in the presence of normal serum levels
Twenty-nine renal transplant recipients with stableof calcitriol suggested vitamin D resistance. Lumbar and femo-
graft function for more than 10 years and serum creati-ral neck osteoporosis was present in 25% and 33% of patients
nine 2 mg/dL were studied. They were classified intoin group A, and 23% and 53% in group B, respectively. T-score
at lumbar spine was negatively correlated with months since two groups according to glomerular filtration rate. Dia-
transplantation. Patients under treatment with cyclosporine betic patients were excluded from the study. None of
(CsA) showed increased concentrations of osteocalcin and the patients was treated with vitamin D metabolites orD-pyr and higher lumbar bone mineral density (BMD), but
calcium supplements or had undergone previous para-bone histomorphometry was not influenced by CsA.
thyroidectomy. All patients provided written informedConclusion. Patients with long-term renal transplantation
with normal renal function frequently present with slight in- consent for participation and bone biopsy. Clinical char-
creases in PTH, but without an effect on bone histology. CsA acteristics are shown in Table 1.
did not induce changes in bone histology and delayed mineral-
ization was frequently observed. Bone biopsies
Transiliac bone biopsies were collected from the ante-
rior iliac crest after double tetracycline labeling and pro-Key words: bone histomorphometry, renal transplantation, cyclospo-
rine. cessed as described previously [7]. Bone turnover was
defined according to activation frequency [7]. 2003 by the International Society of Nephrology
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Table 1. Clinical characteristics
Group A Group B
creatinine clear creatinine clear
All patients 70 mL/min 70 mL/min
N  29 N  12 N  17
Age years 54.411.1 54.88.8 54.112.8
Body mass index kg/m2 26.04.5 26.35.9 25.83.3
Sex male/female 18/11 9/3 9/8
Menopause yes/no 5/6 1/2 4/4
Age at transplant years 41.711.5 41.59.6 41.832.4
Time on dialysis months 42.926.8 43.017.4 42.832.4
Months since transplantation 15640 16655 14926
Serum creatinine mg/dL 1.300.33 1.180.28a 1.380.34a
Creatinine clearance mL/min 85.350 126.155.5a 56.511.5a
Immunosuppresive therapy 12 CsA Pred 2 CsA Pred 10 CsA Pred
10 Aza  Pred 5 Aza  Pred 5 Aza  Pred
4 Triple 2 Triple 2 Triple
2 CsA Aza 2 CsA Aza
1 CsA mono 1 CsA mono
Results are shown as meanSD. Abbreviations are: CsA, cycloporine; Aza, azathioprine; Pred, prednisone.
a P  0.05 vs. creatinine clearance 70 mL/min
Table 2. Biochemical parameters of bone metabolism logic QDR-4500; Hologic Corp., Waltham, MA, USA).
Osteopenia and osteoporosis prevalences were assessedGroup A Group B
creatinine clear creatinine clear according to World Health Organization (WHO) recom-
70 mL/min 70 mL/min Normal mendations [8].N  12 N  17 values
iPTH pg/mL 77.9336.7 107.2465.1 55 Statistical analysis
Calcium mg/dL 9.50.5 9.80.6 8.4–10.5
Phosphorus mg/dL 2.70.4a 3.20.5 3.0–5.0 Results are expressed as mean  SD. Unpaired Stu-
Ca2 mmol/L 1.280.09 1.290.09 1.16–1.35 dent t test was used to compare intergroup diferences.
Osteocalcin ng/mL 28.8617.9 26.4818.3 10.0–40.0
Pearson’s linear correlation was used to detect relation-Alkaline phosphatase U/L 21.159.6 23.4814.5 10.0–22.0
PICP ng/mL 92.8829.7 98.2533.4 69.0–163.0 ships between variables. Computations were performed
ICTP lg/L 4.452.05 5.893.06 1.8–5 using SPSS statistical software (SPSS, Inc., Chicago, IL,OH-proline mol/L Cr 0.01450.006 0.01610.014 0.007–0.025
USA).D-pyr mol/L Cr 8.253.2 7.593.4 2.5–10
25(OH)D ng/mL 34.9516.5 25.217.7 9–37.5
1,25(OH)2D pg/mL 37.419.0a 26.1217.5 15.9–55.6
RESULTSAbbreviations are: PICP, propeptide of type I collagen; ICTP, telopeptide of
type I collagen; OH-proline, urinary hydroxyproline; Cr, creatinine.
The biochemical data for Groups A and B (discusseda P  0.05 vs. Group B
below) are shown in Table 2.
Group A. In spite of normal renal function, mean se-
rum PTH was slightly higher than reference normal values.
Laboratory tests It was elevated in 10 patients. One patient had hypercal-
All samples were obtained the day of bone biopsy. cemia and seven had hypophosphatemia. Biochemical
Immunoradiometric assays were used to determine intact parameters of bone formation (osteocalcin, bone alka-
PTH and osteocalcin. Bone alkaline phosphatase (BAP) line phosphatase, and PICP) and resorption (ICTP,
and propeptide of type I procollagen-PICP were mea- D-pyridinoline, and OH-proline) were within normal lim-
sured by immunoassay. Carboxyterminal telopeptide of its. All patients showed normal levels of 1,25(OH)2D3,
type I collagen-ICTP and 25-hydroxyvitamin D3 were but two patients had low levels of 25(OH)D. Osteopenia
measured by radioimmunoassay (RIA). Total urinary was observed both at lumbar and more severe at femoral
OH-proline was determinated with a colorimetric method neck. Twenty-five percent of patients showed lumbar
and urinary deoxypyridinoline-Dpyr by enzymoimmuno- osteoporosis and 33% showed femoral neck osteoporo-
assay. 1,25 dihydroxyvitamin D3 was determinated by RIA. sis. Bone histomosphometry studies (Table 3) revealed
high bone turnover in three patients, normal bone turn-
Bone densitometry over in eight patients, and only one patient exhibited
low bone turnover. Delayed mineralization was observedBone mineral density (BMD) was evaluated in the
femoral neck and lumbar spine (L1 to L4) by dual energy in three patients and mild aluminum deposits in one.
Group B. Mean serum PTH was elevated in 11 pa-radiographic absorptiometry using a DPX scanner (Ho-
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Table 4. Results according to immunosuppressive therapyTable 3. Histomorphometric parameters
Group A Group B CsA group Non-CsA group
N  19 N  10creatinine clear creatinine clear
70 mL/min 70 mL/min
Sex male/female 11/8 7/3N  12 N  17 Normal values
Menopause yes/no 4/4 1/2
Months since transplantation 13413b 19843BV/TV % 21.037.48a 15.795.15a 21.55.1
Ac.F per year 0.340.33 0.220.20 0.280.12 iPTH pg/mL 97.649.9a 90.269.6
Creatinine clearance mL/min 87.1 56.1a 81.938.1MLT days 62.1663.61 99.82112.75 29.3513.25
Osteocalcin ng/mL 32.420.0b 18.16.6Abbreviations are: BV/TV, bone volume; Ac.F, activation frequency; MLT,
D-pyr mol/L Cr 8.663.5 b 5.871.8mineral lag time.
1,25(OH)2D pg/mL 23.810.8b 43.814.3a P  0.05 vs. Group B
Lumbar BMD g/cm2 0.8940.10b 0.7980.08
Lumbar t-score 1.610.8b 2.540.71
Bone turnover 3 low turnover 8 normal turnover
14 normal turnover 2 high turnover
2 high turnovertients; only in six patients did it remain in normal range.
Three patients were hypercalcemic and five showed hy- a No statistical difference
b P  0.05 vs. non-CsA grouppophosphatemia. Bone remodeling parameters were
within normal range. 1,25(OH)2D3 was below the normal
range in six patients. All patients exhibited normal levels
of 25(OH)D. Patients exhibited osteopenia both at lum- and biochemical or histologic parameters of bone activ-
bar spine and at femoral neck. Neck osteoporosis was ity, with the exception of a negative relationship between
present in 53% of patients and lumbar osteoporosis in T-score at the femoral neck and PTH (r  0.43, P 
23% of patients. In histomorphometric studies (Table 0.05). T-score at the lumbar spine was also correlated
3), two patients had low bone turnover, 14 had normal negatively with months since transplantation (r0.40,
bone turnover, and one had high bone turnover. Seven P  0.05).
patients showed delayed mineralization. Mild aluminum
deposits were found in one patient and peritrabecular Immunosuppressive therapy
fibrosis was found in one patient. The 29 renal transplant patients were classified ac-
cording to the immunosuppressive therapy received:
Bone turnover marker correlations
CsA group (19 patients) and non-CsA group (10 pa-
Serum PTH levels were positively related to serum tients) (Table 4). Histomorphometric data were not dif-
calcium (r  0.44, P  0.05), osteocalcin (r  0.40, P  ferent between the two groups.
0.05), bone alkaline phosphatase (r  0.42, P  0.05),
ICTP (r  0.42, P  0.05), OH-proline (r  0.42, P 
DISCUSSION0.05), and serum creatinine (r  0.49, P  0.01). There
were no significant correlations between serum PTH and This study was designed employing circulating bio-
chemical markers of bone remodeling, bone histomor-histomorphometric parameters.
Osteocalcin correlated significantly with all the other phometry, and densitometry to investigate bone disease
in long-term adult renal recipients with normal renalmarkers. Correlations between osteocalcin and BAP and
propeptide as markers of bone formation reached statis- function.
Persistent hyperparathyroidism was detected in 43%tical significance within the group as a whole (r  0.40,
P  0.05; r  0.50, P  0.01, respectively). OH-proline of long-term renal transplant patients with a serum creat-
inine 1.5 mg/dL [9]. In this study, according to activa-and D-Pyr as markers of bone resorption also correlated
significantly (r  0.61, P  0.001). In contrast, calcitriol tion frequency, only three patients out of 12 with normal
renal function exhibited high bone turnover. Therefore,levels did not correlate significantly with PTH or other
biochemical markers. although past studies have reported a high frequency
of parathyroid overactivity in renal transplant patientsNegative relationships were also observed between
bone volume and telopeptide (r  0.47, P  0.05), based on PTH levels, there is no histologic data to sup-
port overactivity on bone. Corticosteroids most likelyOH-proline (r0.39, P 0.05), and D-Pyr (r0.40,
P  0.05). Osteoclast surface was positively correlated counterbalance the bone effects of PTH.
Studies in renal transplant recipients measuring vita-with osteocalcin (r  0.37, P  0.05), telopeptide (r 
0.42, P 0.05), and D-pyr (r 0.40, P 0.05). Calcitriol min D metabolites have given conflicting results [10]. In
the present study, in the group with GFR 70 mL/min,levels correlated with bone formation rate, activation
fraction, and mineralizing surface (P  0.05). No signifi- all patients had levels of 1,25(OH)D within the normal
range, indicating the success of transplantation in restor-cant correlations were found between PTH, BAP, and
propeptide with histomorphometric parameters. ing 1-hydroxylase activity. On the other hand, in the
group with GFR 70 mL/min, six patients had levels ofNo significant correlations were found between BMD
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ogy, Hospital Universitario Valdecilla, Universidad de Cantabria, San-1,25(OH)D below the normal range, with normal levels
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ported in early renal insufficiency explains this observa-
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